The antithrombotic activity and pharmaco- kinetics of enoxaparine, a low molecular weight heparin, in humans given single subcutaneous doses of 20 to 80 mg. J Clin Pharmacol. 1988;28(7):609-618.Frydman AM, Bara L, Le Roux Y, Woler M, Chauliac F, Samama MM. The antithrombotic activity...
de Vries JI, van Pampus MG, Hague WM, Bezemer PD, Joosten JH, Investigators F. Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT. J Thromb Haemost. 2012;10(1):64–72. Article PubMed...
While the affinity of AAT binding to TMPRSS2 is modest based on molecular modeling, this interaction may be enhanced in vivo because the plasma level of endogenous UFH is 1 to 2.4 mg/L, equivalent to 0.5 to 1.2 units/ mL38. While our model showed that a 4mer of negatively-charged...
After a 3-day course of pulse therapy, continued treatment with methylprednisolone (2 mg/kg/day) was prescribed. However, 4 days later, an increase in CRP level to 4.22 mg/dL and pyuria were noted, while echocardiography revealed progressive changes in the coronary aneurysms, with the diameters...
We enrolled 40 acute venous thromboembolism cases prospectively and matched them by age, gender, and location of venous thromboembolism to 80 previously treated controls. All controls had received enoxaparin 1 mg/kg twice daily. The primary end point was recurrent venous thromboembolism. We followed ...
once daily according to body weight: 60mg for 45–60kg, 80mg for 61–100kg or 100mg for >100kg for 14days, with dose adjustment according to anti-factor Xa activity (target range: 0.4–0.6 UI/ml); an observational cohort (OC) included patients receiving enoxaparin 40mgday for ...
Given limitations in the currently available armamentarium for treatment of ON, in a prospective pilot study our hypothesis was that enoxaparin (60 mg/day, 12 weeks) would prevent progression of stage I-II hip ON associated with thrombophilia-hypofibrinolysis over ≥ 108 weeks follow-up versus ...
Results: A total of 62 patients were enrolled and randomized to 1 mg/kg (n = 32) or 0.8 mg/kg (n = 30), and 54 patients completed the study. The study did not meet accrual for 80% power. Goal anti-Xa levels were achieved in a similar proportion for the reduced-dose (n = 25...
Likewise, enoxaparin at the doses tested had similar efficacy but with a significantly prolonged bleeding time at the 1 mg/kg bolus dose. WE might provide a safer alternative to heparins in the treatment of acute progressive thrombosis.
Objective: The aim of this study was to determine the bioequivalence of generic (test) and branded (reference) formulations of enoxaparin 60 mg (6000 IU anti-Xa) SC in healthy subjects for the purpose of meeting regulatory requirements for marketing the generic formulation in China. Methods: ...